GRAL

GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law

Grail Class Action Over NHS-Galleri Trial Could Pressure GRAL Stock

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>A securities class action targets Grail over NHS-Galleri trial statements and data omissions, alleging false statements about reducing Stage III-IV cancers. The lead-plaintiff deadline is August 4, 2026, and the class period spans May 13, 2025 to February 19, 2026. Resolution risk could weigh sentiment and GRAL&#039;s valuation until a determination or settlement occurs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Grail named in securities class action alleging misstatements.</li><li>Lead-plaintiff deadline Aug 4, 2026; class period May 13, 2025–Feb 19, 2026.</li><li>Alleges Grail overstated NHS-Galleri trial prospects and concealed adverse data.</li><li>Case not certified yet; investors may suffer damages if successful.</li><li>SBS invites lead plaintiffs; contact details issued.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Grail, Inc. (GRAL)</strong>: Subject of the suit; alleged misstatements regarding NHS-Galleri trial; potential valuation impact.</li><li><strong>Schall, Brown &amp; Schwartz LLP (N/A)</strong>: Plaintiff law firm behind the suit; promotional PR; not a market actor.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits due to securities class-action context and potential accountability risks for Grail.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Potential price pressure if the lawsuit gains traction or new filings emerge.</li><li>Allegations focus on NHS-Galleri data, which could affect sentiment and funding access.</li><li>Case status is not certified; near-term volatility depends on developments.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period: May 13, 2025 to February 19, 2026.</li><li>Deadline for lead-plaintiff applications: August 4, 2026.</li><li>Plaintiff alleges Grail issued false and misleading statements about the NHS-Galleri trial.</li><li>GRAL ticker: NASDAQ GRAL.</li><li>Filed by Schall, Brown &amp; Schwartz LLP.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to modestly negative near term; potential downside if litigation gains momentum within 6–12 months.</p>
  </section>
</section>


<article>
  <p>LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GRAIL, Inc. ("Grail" or "the Company") (NASDAQ: GRAL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
  <p>Shareholders who purchased shares of GRAL during the class period listed are encouraged to contact the firm regarding possible <em>lead plaintiff appointments</em>. Appointment as lead plaintiff is <em>not required to partake in any recovery</em>.</p>

  <section>
    <h2>Key Facts for GRAL Investors</h2>
    <ul>
      <li><strong>Stock symbol:</strong> GRAL (GRAIL, Inc. on NASDAQ)</li>
      <li><strong>CLASS PERIOD:</strong> May 13, 2025 to February 19, 2026</li>
      <li><strong>DEADLINE:</strong> August 4, 2026</li>
      <li><strong>Lead plaintiff opportunity:</strong> possible appointments; not required to pursue recovery</li>
    </ul>
  </section>

  <section>
    <h2>Class Period and Participation Timeline</h2>
    <p><strong>CLASS PERIOD:</strong> May 13, 2025 to February 19, 2026</p>
    <p><strong>DEADLINE:</strong> August 4, 2026</p>
  </section>

  <section>
    <h2>Case Details: Allegations Against GRAIL</h2>
    <p><strong>CASE DETAILS:</strong> According to the Complaint, the Company made false and misleading statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company’s optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year timeframe was insufficient to demonstrate the successful achievement of the study’s primary endpoint. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Grail, investors suffered damages.</p>
  </section>

  <section>
    <p>We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm&#39;s website at <a href="https://www.schallfirm.com" target="_blank" rel="nofollow"><u>www.schallfirm.com</u></a>, or by email at <a href="mailto:david@schallfirm.com" rel="nofollow" target="_blank">david@schallfirm.com</a>.</p>
  </section>

  <section>
    <p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
    <p><a href="https://www.globenewswire.com/Tracker?data=Z_TRkmLgPcH5le7Zxm1GGyzYTXb1PoDgjDRl7krEWj6b5E9gMObqmwPHQXcyzf-41oQfjhtxHuQaxu3uTiNBEOndATWqKsI5BlX9FxuCoq0=" rel="nofollow" target="_blank">Join the case</a> to recover your losses.</p>
  </section>

  <section>
    <h2>Why SBS? Expertise in Securities Class Actions</h2>
    <p><strong>WHY SBS?</strong> Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.</p>
  </section>

  <section>
    <h2>Contact Schall, Brown & Schwartz LLP</h2>
    <p>Schall, Brown & Schwartz LLP<br>Brian Schall, Esq.,<br>Andrew Brown, Esq.,<br>David Schwartz, Esq.,<br><a href="https://www.schallfirm.com" target="_blank" rel="nofollow">www.schallfirm.com</a><br>Office: 310-301-3335<br><a href="mailto:info@schallfirm.com" target="_blank" rel="nofollow"><u>info@schallfirm.com</u></a></p>
  </section>

  <section>
    <h2>Source</h2>
    <p>Schall, Brown & Schwartz LLP</p>
  </section>

  <p><strong>Note:</strong> This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
</article>

A securities class action targets Grail over NHS-Galleri trial statements and data omissions, alleging false statements about reducing Stage III-IV cancers. The lead-plaintiff deadline is August 4, 2026, and the class period spans May 13, 2025 to February 19, 2026. Resolution risk could weigh sentiment and GRAL's valuation until a determination or settlement occurs.

News insight

GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law

AI summary

Sentiment rationale

Key facts

Legal